Skip to main content
Premium Trial:

Request an Annual Quote

The Repurpose

The Broad Institute will be searching through Roche's catalog of more than 300 failed compounds to find new possible uses for those drugs, Fierce Biotech reports. "Presumably, those compounds passed initial safety tests, meaning that renewed development for a new use might not require as much lengthy (and expensive) study as a never-before-trialed drug," Fierce Biotech writes. Similar drug repurposing efforts are underway at the US National Institutes of Health's National Center for Translational Science and at the UK's Medical Research Council.

At In the Pipeline, Derek Lowe writes that he hopes something comes out of this new initiative, but he adds that it'll be a tricky challenge. "The best case for any repurposed compound is for its original target to be good for something unanticipated," he says, later adding that "it's not that I think these shouldn't be tried — why not, as long as it doesn't cost too much — but things could quickly get more complicated than they might have seemed."

The Scan

Could Mix It Up

The US Food and Drug Administration is considering a plan that would allow for the mixing-and-matching of SARS-CoV-2 vaccines and boosters, the New York Times says.

Closest to the Dog

New Scientist reports that extinct Japanese wolf appears to be the closest known wild relative of dogs.

Offer to Come Back

The Knoxville News Sentinel reports that the University of Tennessee is offering Anming Hu, a professor who was acquitted of charges that he hid ties to China, his position back.

PNAS Papers on Myeloid Differentiation MicroRNAs, Urinary Exosomes, Maize Domestication

In PNAS this week: role of microRNAs in myeloid differentiation, exosomes in urine, and more.